Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma

Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the questio...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchegger, Franz, Press, Oliver W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251040/
https://www.ncbi.nlm.nih.gov/pubmed/22214546
http://dx.doi.org/10.1186/2191-219X-1-7
_version_ 1782220517819809792
author Buchegger, Franz
Press, Oliver W
author_facet Buchegger, Franz
Press, Oliver W
author_sort Buchegger, Franz
collection PubMed
description Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy.
format Online
Article
Text
id pubmed-3251040
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-32510402012-02-03 Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma Buchegger, Franz Press, Oliver W EJNMMI Res Letter to the Editor Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy. Springer 2011-06-20 /pmc/articles/PMC3251040/ /pubmed/22214546 http://dx.doi.org/10.1186/2191-219X-1-7 Text en Copyright © 2011 Buchegger and Press; licensee Springer. https://creativecommons.org/licenses/by/2.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0 (https://creativecommons.org/licenses/by/2.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Buchegger, Franz
Press, Oliver W
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title_full Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title_fullStr Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title_full_unstemmed Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title_short Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
title_sort radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251040/
https://www.ncbi.nlm.nih.gov/pubmed/22214546
http://dx.doi.org/10.1186/2191-219X-1-7
work_keys_str_mv AT bucheggerfranz radioimmunotherapyconsolidationandrituximabmaintenanceintheinitialtreatmentoffollicularlymphoma
AT pressoliverw radioimmunotherapyconsolidationandrituximabmaintenanceintheinitialtreatmentoffollicularlymphoma

Ejemplares similares